An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy—a retrospective cohort study examining 66 circulating immune cell subsets

INTRODUCTION: Immune checkpoint blockade inhibitor (ICI) therapy offers significant survival benefits for malignant melanoma. However, some patients were observed to be in disease progression after the first few treatment cycles. As such, it is urgent to find convenient and accessible indicators tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Peidong, Jiang, Hang, Li, Dandan, Li, Jingjing, Wen, Xizhi, Ding, Qiyue, Chen, Linbin, Zhang, Xiaoshi, Huang, Junqi, Ding, Ya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768215/
https://www.ncbi.nlm.nih.gov/pubmed/36569825
http://dx.doi.org/10.3389/fimmu.2022.1012673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768215/
https://www.ncbi.nlm.nih.gov/pubmed/36569825
http://dx.doi.org/10.3389/fimmu.2022.1012673

Ejemplares similares